Elite Pharmaceuticals (ELTP) Director Dash Buys $26K of Stock
Key Points
- Elite Pharmaceuticals Inc director Barry H Dash bought 100,000 shares at $0.26 per share on October 9, 2026, spending $25,980 in total.
- The transaction grew the director's holdings by 3.06% to a total of 3,365,555 shares.
- The specialty pharmaceutical company recently trades around $0.25, below its 50-day moving average of $0.27.
Since the trade, $ELTP is down 3.9% after 1 week and down 3.9% to date (from the $0.26 close on Oct 9, 2026).
Get Elite Pharmaceuticals text alerts
We text you when insiders, Congress, analysts or big funds move on $ELTP.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Elite Pharmaceuticals, Inc. alert may contain errors. Disclosures
Elite Pharmaceuticals Inc director Barry H Dash bought 100,000 shares of the company on October 9, 2026. According to a Form 4 filed with the SEC, the insider picked up the stock at a price of $0.26 per share for a total value of $25,980.
ELTP
Elite Pharmaceuticals, Inc.
Barry H Dash vs. the S&P 500
Hypothetical returns from Barry H Dash's disclosed trades, not real profit or advice. How we model this.
Inside Barry H Dash's Elite Pharmaceuticals Trade
The purchase expanded Dash's direct holdings by a 3.06% margin. Following the transaction, the director holds a total of 3,365,555 shares in the specialty pharmaceutical company. The trade was executed in the open market and was not part of a pre-arranged Rule 10b5-1 trading plan.
Other Institutional Activity in Elite Pharmaceuticals
Other institutional players have also adjusted their positions in the drug maker recently. Kelleher Financial Advisors grew its holdings by 500 shares, ending with 1,000 shares worth about $250.
Elite Pharmaceuticals, Inc. Stock Holds Steady
Elite Pharmaceuticals shares recently traded around $0.25. That level sits about 8.6% below its 50-day moving average of $0.27 and roughly 30.7% below its 200-day moving average of $0.36. The stock has traded between a 52-week low of $0.21 and a 52-week high of $0.69, putting the recent price up about 19.0% from its lowest point over the past year.
Recent Earnings
The company posted trailing-twelve-month revenue of $141.0 million and earnings of $0.04 per share. Elite Pharmaceuticals maintains a net profit margin of 40.2% and a return on equity of 74.3%. The next earnings report is scheduled for November 12, 2026.
Insider Buying and Selling at Elite Pharmaceuticals, Inc.
Insiders have been active in the stock over the past year and a half. On July 10, 2025, officer Kirko Kirkov bought 16,366 shares at $0.59 each for $9,640. Later, on August 22, 2025, an insider entity sold 500,000 shares at $0.52 for a total of $262,150. Officer Douglas Plassche then sold 800,000 shares on October 2, 2025, at $0.62 apiece, totaling $499,200. More recently, Barry H Dash bought 30,000 shares on August 19, 2026, at $0.29 per share for a total value of $8,610.
About Elite Pharmaceuticals
Elite Pharmaceuticals, Inc. operates out of Northvale, New Jersey, employing 65 people. The specialty pharmaceutical company focuses on developing, manufacturing, and selling oral, controlled-release products along with generic medications.
Bottom Line
Investors tracking insider sentiment at Elite Pharmaceuticals will note the director's ongoing accumulation of shares. The company's upcoming earnings release on November 12, 2026, will offer fresh details on its financial trajectory.
Related Filing Alerts
Source: Barry H Dash's Form 4 filing on $ELTP (Oct 9, 2026). Written by software, not financial advice. How we make alerts